SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
SEC Accession No. 0001387131-22-001705
Filing Date
2022-02-11
Accepted
2022-02-11 17:04:13
Documents
2
Group Members
ATLAS VENTURE ASSOCIATES OPPORTUNITY I, L.P.ATLAS VENTURE ASSOCIATES OPPORTUNITY I, LLCATLAS VENTURE ASSOCIATES XI, L.P.ATLAS VENTURE ASSOCIATES XI, LLCATLAS VENTURE OPPORTUNITY FUND I, L.P.

Document Format Files

Seq Description Document Type Size
1 AMENDMENT TO SC 13G dyn-sc13ga_123121.htm SC 13G/A 100377
2 EXHIBIT A - JOINT FILING AGREEMENT ex-a.htm EX-1 14824
  Complete submission text file 0001387131-22-001705.txt   116956
Mailing Address 400 TECHNOLOGY SQUARE 10TH FLOOR CAMBRIDGE MA 02139
Business Address 400 TECHNOLOGY SQUARE 10TH FLOOR CAMBRIDGE MA 02139 857-201-2700
Atlas Venture Fund XI, L.P. (Filed by) CIK: 0001708269 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A

Mailing Address 830 WINTER STREET WALTHAM MA 02451
Business Address 830 WINTER STREET WALTHAM MA 02451 (781) 786-8230
Dyne Therapeutics, Inc. (Subject) CIK: 0001818794 (see all company filings)

IRS No.: 364883909 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-91706 | Film No.: 22622488
SIC: 2834 Pharmaceutical Preparations